Aldeyra Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
ALDX$0.63+2.9%Stored close · as of Nov 6, 2026
Contents
Consolidated Balance Sheets at March 31, 2026 (Unaudited) and December 31, 2025
CONSOLIDATED BALANCE SHEETS
| March 31, | ||
|---|---|---|
| 2026 | December 31, | |
| (unaudited) | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $65,002,305 | $70,041,254 |
| Prepaid expenses and other current assets | 1,271,514 | 1,742,202 |
| Total current assets | 66,273,819 | 71,783,456 |
| Right-of-use assets | 209,262 | 275,861 |
| Total assets | $66,483,081 | $72,059,317 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $141,356 | $158,461 |
| Accrued expenses | 2,672,164 | 6,120,297 |
| Current portion of debt | 15,300,000 | 15,249,632 |
| Operating lease liabilities | 212,769 | 280,537 |
| Deferred collaboration revenue | 6,000,000 | 6,000,000 |
| Total current liabilities | 24,326,289 | 27,808,927 |
| Total liabilities | 24,326,289 | 27,808,927 |
| Commitments and contingencies (Notes 3, 9, & 14) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding | — | — |
| Common stock, voting, $0.001 par value; 150,000,000 authorized and 60,321,068 and 60,162,773 shares issued and outstanding, respectively | 60,321 | 60,163 |
| Additional paid-in capital | 529,506,343 | 528,147,480 |
| Accumulated deficit | (487,409,872) | (483,957,253) |
| Total stockholders’ equity | 42,156,792 | 44,250,390 |
| Total liabilities and stockholders’ equity | $66,483,081 | $72,059,317 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.